Galectin Therapeutics (GALT) Preferred Stock Liabilities (2011 - 2026)

Galectin Therapeutics has reported Preferred Stock Liabilities for 16 years, with the latest figure at $1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Preferred Stock Liabilities changed 0.0% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (changed 0.0% YoY), and the FY2025 full-year result was $1.7 million, changed 0.0% from the prior year.
• Preferred Stock Liabilities for Q1 2026 stood at $1.7 million, roughly flat from $1.7 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $1.7 million in Q1 2022, with the low at $1.7 million in Q1 2022.
• Average Preferred Stock Liabilities over 5 years is $1.7 million, with a median of $1.7 million recorded in 2022.
• Peak annual rise in Preferred Stock Liabilities reached 0.0% in 2022, while the deepest fall reached 0.0% in 2022.
• Tracing GALT's Preferred Stock Liabilities over 5 years: stood at $1.7 million in 2022, then changed by 0.0% to $1.7 million in 2023, then changed by 0.0% to $1.7 million in 2024, then changed by 0.0% to $1.7 million in 2025, then changed by 0.0% to $1.7 million in 2026.
• The last three Preferred Stock Liabilities figures came in at $1.7 million (Q1 2026), $1.7 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.

Peer Comparison